title: Poorly-controlled acromegaly accompanied by subclinical adrenal Cushing's syndrome after surgery for multiple endocrine tumors.
abstract: A 48-year-old woman diagnosed with acromegaly 21 years earlier presented at our hospital with a left adrenal tumor. Her medical history included breast cancer, thyroid cancer and an incompletely resected growth hormone (GH)-producing pituitary adenoma. Endocrinological and radiological examinations revealed subclinical adrenal Cushing's syndrome. She subsequently underwent left adrenalectomy, followed by glucocorticoid replacement therapy. Her GH and insulin-like growth factor-1 levels were insufficiently controlled, and pegvisomant was administered in addition to octreotide acetate. Following adrenalectomy, a giant hepatic hemangioma and papillary thyroid carcinoma in the residual right lobe developed, indicating the high risk of tumor development in patients with acromegaly.
authors: Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan.
authors: Motoko
authors: M
authors: Ishikawa
authors: Masako
authors: M
authors: Kato
authors: Hiroshi
authors: H
authors: Sasaki
authors: Tsukasa
authors: T
authors: Morii
authors: Hiroki
authors: H
authors: Fujita
authors: Masafumi
authors: M
authors: Kakei
authors: Takuma
authors: T
authors: Narita
authors: Yuichiro
authors: Y
authors: Yamada
mesh_terms: D000172:Acromegaly / Q000209:etiology* / Q000628:therapy; D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000628:therapy*; D000315:Adrenalectomy; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications; D002277:Carcinoma / Q000209:etiology; D002291:Carcinoma, Papillary; D003480:Cushing Syndrome / Q000209:etiology* / Q000628:therapy; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000150:complications* / Q000628:therapy*; D006391:Hemangioma / Q000209:etiology; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008113:Liver Neoplasms / Q000209:etiology; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage; D010911:Pituitary Neoplasms / Q000150:complications* / Q000628:therapy*; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000150:complications / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; C406545:pegvisomant; D015282:Octreotide